QMS Medical Allied Services Migrates to NSE Mainboard; Targets Rs. 500 Crore Revenue by FY29
QMS Medical Allied Services Limited has migrated to the NSE Mainboard, effective June 18, 2026. The company reported FY26 consolidated revenues of ₹172.9 crore and EBITDA of ₹25.9 crore. QMS aims to reach ₹500 crore in consolidated revenue by FY29, with its Services business expected to double by FY27.
The migration to the mainboard is expected to increase liquidity, attract institutional investors, and enhance the company's visibility, which can positively impact its valuation and access to capital. The clear revenue targets also provide a strong growth outlook.
The migration to the NSE Mainboard is a significant corporate milestone, reflecting strong operational and financial performance. The company has also set ambitious revenue targets, indicating confidence in future growth.
QMS Medical Allied Services Limited (QMSMEDI) has successfully migrated to the Mainboard of the National Stock Exchange (NSE) from NSE Emerge, effective June 18, 2026. The company's 1.93 crore equity shares, with a face value of Rs. 10 each, are now tradable on the mainboard. This migration signifies QMS's operational scale, financial performance, and strong governance standards.
The company recorded consolidated revenues of ₹172.9 crore and EBITDA of ₹25.9 crore during FY26. QMS aims to capitalize on the shift in pharma marketing towards patient-focused engagement. The Services business, including Patient Screening camps and Patient Service Programs, is expected to double in revenue by FY27 and contribute approximately 50% of total revenues by FY29. The Product business is projected to grow through expanded distribution, own brands, self-manufacturing, and international partnerships.
Commenting on the milestone, Mahesh Makhija, Chairman & Managing Director, stated, "Our listing on NSE Mainboard is a defining milestone in QMS’s evolution and reflects the strong foundation we have built over the years." He added, "We are now setting sights on tripling our revenues in the next three years," targeting ₹500 crore in consolidated revenue by FY2029. The company has supported over 10 lakh patients and partnered with more than 50 pharmaceutical and healthcare companies.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.